Logo image of BLPH

BELLEROPHON THERAPEUTICS INC (BLPH) Stock Fundamental Analysis

NASDAQ:BLPH - Nasdaq - US0787713009 - Common Stock - Currency: USD

0.1025  -0.28 (-73.39%)

After market: 0.114 +0.01 (+11.22%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BLPH. BLPH was compared to 555 industry peers in the Biotechnology industry. BLPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BLPH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BLPH has reported negative net income.
In the past year BLPH has reported a negative cash flow from operations.
BLPH had negative earnings in 4 of the past 5 years.
BLPH had a negative operating cash flow in each of the past 5 years.
BLPH Yearly Net Income VS EBIT VS OCF VS FCFBLPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M -40M -50M

1.2 Ratios

BLPH's Return On Assets of -110.28% is on the low side compared to the rest of the industry. BLPH is outperformed by 81.59% of its industry peers.
BLPH's Return On Equity of -220.54% is on the low side compared to the rest of the industry. BLPH is outperformed by 74.63% of its industry peers.
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROIC N/A
ROA(3y)-121.74%
ROA(5y)-90.23%
ROE(3y)-309.79%
ROE(5y)-245.24%
ROIC(3y)N/A
ROIC(5y)N/A
BLPH Yearly ROA, ROE, ROICBLPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 1K 1.5K 2K

1.3 Margins

BLPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLPH Yearly Profit, Operating, Gross MarginsBLPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

BLPH has more shares outstanding than it did 1 year ago.
BLPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BLPH Yearly Shares OutstandingBLPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M
BLPH Yearly Total Debt VS Total AssetsBLPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

BLPH has an Altman-Z score of -34.54. This is a bad value and indicates that BLPH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -34.54, BLPH is doing worse than 94.86% of the companies in the same industry.
There is no outstanding debt for BLPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.54
ROIC/WACCN/A
WACCN/A
BLPH Yearly LT Debt VS Equity VS FCFBLPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 2.00 indicates that BLPH has no problem at all paying its short term obligations.
With a Current ratio value of 2.00, BLPH is not doing good in the industry: 81.92% of the companies in the same industry are doing better.
A Quick Ratio of 2.00 indicates that BLPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.00, BLPH is doing worse than 80.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 2
BLPH Yearly Current Assets VS Current LiabilitesBLPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

BLPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.27%, which is quite impressive.
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BLPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.86% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.96%
EPS Next 2Y5.24%
EPS Next 3Y39.61%
EPS Next 5Y22.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLPH Yearly Revenue VS EstimatesBLPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
BLPH Yearly EPS VS EstimatesBLPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLPH Price Earnings VS Forward Price EarningsBLPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLPH Per share dataBLPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

BLPH's earnings are expected to grow with 39.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y39.61%

More info and screens

0

5. Dividend

5.1 Amount

BLPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELLEROPHON THERAPEUTICS INC

NASDAQ:BLPH (10/13/2023, 8:00:02 PM)

After market: 0.114 +0.01 (+11.22%)

0.1025

-0.28 (-73.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-13 2023-11-13/bmo
Inst Owners0.13%
Inst Owner Change0%
Ins Owners192.64%
Ins Owner Change0%
Market Cap1.25M
Analysts43.33
Price Target2.04 (1890.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.72%
Min EPS beat(2)1.96%
Max EPS beat(2)153.48%
EPS beat(4)3
Avg EPS beat(4)39.59%
Min EPS beat(4)-8.25%
Max EPS beat(4)153.48%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.53%
EPS NY rev (1m)0%
EPS NY rev (3m)28.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-21.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.46
BVpS0.46
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.74%
ROA(5y)-90.23%
ROE(3y)-309.79%
ROE(5y)-245.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 2
Altman-Z -34.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.33%
EPS Next Y50.96%
EPS Next 2Y5.24%
EPS Next 3Y39.61%
EPS Next 5Y22.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.17%
OCF growth 3YN/A
OCF growth 5YN/A